Citing "seriously flawed" methodology and "unjustified" claims, the journal Vaccine has permanently withdrawn a previously published study critical of Merck's Gardasil.
The China FDA has approved cervical disease test CINtec PLUS Cytology from Basel-based Roche, bolstering the company's offering in China where nearly 62,000 new cases of cervical cancer are reported annually.
Merck, GlaxoSmithKline and public health officials in the United States have some big new numbers to tout to promote HPV vaccination. On Monday, a group of federal researchers said that since the introduction of Gardasil in 2006, HPV infection rates in teenage girls have fallen by nearly two-thirds.
Merck and GlaxoSmithKline have spent years working to build the market for their HPV vaccines, and a new study may demonstrate one factor that has hindered their efforts.
A new study published in the Journal of Adolescent Health found that parents looking online for information about HPV vaccines can be misled by websites containing inaccurate or incomplete medical information, Reuters reported.
Suggesting that India's chief drug regulator may not be doing enough to protect certain volunteers in clinical trials, the Supreme Court ordered the agency to provide adequate oversight, particularly when drugs to treat the human papillomavirus are concerned.
For years, Merck and GlaxoSmithKline have battled safety worries and other stigmas with their HPV vaccines. But this week, the companies received a piece of positive news from the European Medicines Agency, which reported that a committee found no link between the shots and two rare conditions it had been studying.
Roche won a contract in the Netherlands to provide its HPV test for primary screening of cervical cancer through the country's national cervical cancer screening program, a milestone for the company more than a year after its scored FDA approval for its diagnostic for frontline HPV testing.
While the European Medicines Agency said it "does not question that the benefits of HPV vaccines outweigh their risks," on Monday it announced a safety review of the shots that have thus far failed to live up to expectations partly due to safety concerns and a sex-related stigma.
Immuno-oncology innovator Kite Pharma is joining gene therapy luminary bluebird bio to craft new treatments for HPV-related cancers, combining two high-profile technologies in hopes of developing targeted therapies.